| Ytd | 84.48% | |
| 1y | 342.15% |
| Open | 5.39 | Prev Close | 5.47 | Low | 5.31 | High | 5.53 | Mkt Cap | 426.95M |
| Vol | 99.51K | Avg Vol | 476.43K | EPS | -0.73 | P/E | N/A | Forward P/E | -0.82 |
| Beta | 0.96 | Short Ratio | 7.51 | Inst. Own | 84.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 4.93 | 200-d Avg | 3.52 | 1yr Est | 5.00 |
PRLD News
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday&
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the ana
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a
U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the ana
D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) w
Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmar
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a
In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 s
Title: First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, driv
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that
Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperf
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.20) per share which missed the a
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying pot
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Progr
Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD) and AbCellera (NASDAQ:ABCL) toda
Tuesday saw 132 companies set new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.
Wednesday's session saw 150 companies set new 52-week lows.
On Tuesday, 210 companies reached new 52-week lows.
During Wednesday's trading, 103 companies set new 52-week lows.
U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list
On Friday, 1043 companies hit new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.